AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.
Adam Colborn, JD
Advertisement
Adam Colborn is vice president of government affairs at AMCP.
Articles by Adam Colborn, JD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Reshoring Update: BMS Commits $2.3B to Houston Campus
2
Escalating Iran Standoff and Red Sea Attacks Raise Freight Risk for Pharma Supply Chains
3
Health Plans, PBMs Wary of TrumpRx Impact on Patients
4
FDA Launches Small Dispenser Assessment, Grants DSCSA Exemptions
5